Azora Therapeutics (AZR) closed at $3.51 on November 11, 2026, down 6.6% from the previous close, on volume of 11,003 shares (30-day average 67,389).
Data as of November 11, 2026.
Azora Therapeutics Appoints New Independent Directors, Reshapes Board
TipRanks (Mon, 9-Nov 8:00 AM ET)
Azora’s AhR-Focused AT177 Supports Buy Thesis; $14 Price Target Unchanged
TipRanks (Sun, 8-Nov 7:45 PM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.
Azora Therapeutics trades on the NASDAQ stock market under the symbol AZR.
As of November 12, 2026, AZR stock price climbed to $4.04 with 48,674 million shares trading.
AZR has a market cap of $10.61 million. This is considered a Sub-Micro Cap stock.
AZR support price is $2.98 and resistance is $4.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZR shares will trade within this expected range on the day.